Biocon Limited

rs,

4, 2023 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, To, The Secretary National

38%

M M A R Y : F Y 2 3 T O T A L I N C O M E Strong revenue growth over last year, Total Revenues up 38% Completion of the landmark acquisiton of Viatris’ biosimilar business; strategic investment to acc

rs 5,584

continue to earn global recognition In INR Cr FY23 FY22 YoY % Generics 2,637 2,341 Biosimilars 5,584 3,464 13 61 Novels 19 51 Research Services 3,193 2,604 23 Intersegment (258) (276) Reve

1.9 billion

mfortably serviced Plan to raise additional equity at the BBL level during FY24 Net Debt* at ~USD 1.9 billion as of Dec 2022 Stake sale in Syngene (USD 270 million) Investment by Kotak (USD 130 million) Con

270 million

the BBL level during FY24 Net Debt* at ~USD 1.9 billion as of Dec 2022 Stake sale in Syngene (USD 270 million) Investment by Kotak (USD 130 million) Conversion of loan to equity in BBL by Serum (USD 150 mil

130 million

~USD 1.9 billion as of Dec 2022 Stake sale in Syngene (USD 270 million) Investment by Kotak (USD 130 million) Conversion of loan to equity in BBL by Serum (USD 150 million) Investment by Edelweiss (USD 98

150 million

million) Investment by Kotak (USD 130 million) Conversion of loan to equity in BBL by Serum (USD 150 million) Investment by Edelweiss (USD 98 million) Current Net Debt* at USD 1.25 billion Net Debt* reduce

98 million

ion) Conversion of loan to equity in BBL by Serum (USD 150 million) Investment by Edelweiss (USD 98 million) Current Net Debt* at USD 1.25 billion Net Debt* reduced by ~USD 650 million *Excludes structure

1.25 billion

BBL by Serum (USD 150 million) Investment by Edelweiss (USD 98 million) Current Net Debt* at USD 1.25 billion Net Debt* reduced by ~USD 650 million *Excludes structured investments B I O C O N L I M I T E D

650 million

ent by Edelweiss (USD 98 million) Current Net Debt* at USD 1.25 billion Net Debt* reduced by ~USD 650 million *Excludes structured investments B I O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N

1 %

Q4 FY23 Consolidated (in ₹ Cr.) Q4 FY23 Q4 FY22 YoY % Total Revenue 3,929 2,476 Core EBITDA1 % Margin EBITDA % Margin Profit Before Tax (Before exceptional charge) % Margin Net Profit (Bef

35%

exceptional charge) % Margin Net Profit (Before exceptional charge) Net Profit Margin % 1,260 35% 1,152 29% 500 13% 335 9% 809 33% 659 27% 384 15% 262 11% 59 56 75 30 28 Biosimi